The medications used in targeted therapy arrest the proliferation of melanoma that constituted mutated serine/threonine-protein kinase B-Raf (BRAF), Mitogen-activated protein kinase (MEK), or tyrosine-protein kinase Kit (C-KIT) genes. The gene discussed is BRAF; the disease is melanoma.